Low-dose rivaroxaban for dialysis patients without blood thinners
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a lower dose of the blood thinner rivaroxaban is safe for people with kidney failure on dialysis who do not already need blood thinners. The goal is to find a way to prevent blood clots and strokes with less risk of bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been on chronic hemodialysis (kidney dialysis) for at least 3 months.
- You are not already taking a long-term blood thinner (like for atrial fibrillation or blood clots).
- You do not have a high risk of bleeding (such as a history of serious bleeding, low platelets, or active cancer in the digestive or urinary tract).
- You are not taking medications that could interfere with the study drug (like rifampin or St. John's Wort).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a low-dose blood thinner called rivaroxaban, given for 90 days after a recent ischemic stroke, to see if it reduces the risk of another stroke or heart problems. It may be an option for people who are already receiving standard stroke care and are not on full-dose blood thinners.
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
Hear when a new Chronic Hemodialysis Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.